Company news

Assertio Holdings, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Assertio Holdings, Inc. to Report First Quarter 2021 Financial Results After the Close of Markets on Thursday, May 6, 2021

April 21, 2021

Assertio Reports Fourth Quarter and Full Year 2020 Financial Results

March 10, 2021

Assertio Holdings, Inc. to Report Fourth Quarter and Full Year 2020 Financial Results After the Close of Markets on Thursday, March 11, 2021

February 17, 2021

Assertio Holdings, Inc. Announces Closing of Registered Direct Offering of $34.3 Million

February 11, 2021

Assertio Holdings, Inc. Announces Pricing of $34.3 Million Registered Direct Offering

February 9, 2021

Assertio Holdings, Inc. Announces Closing of Registered Direct Offering of $14 Million

February 8, 2021

Assertio Holdings, Inc. Announces Pricing of $14 Million Registered Direct Offering

February 4, 2021

Assertio Announces $5.0 Million Insurance Settlement and General Corporate Updates

February 2, 2021

Assertio Announces Transfer of Listing from Nasdaq Global Select Market to Nasdaq Capital Market

December 28, 2020

Assertio Announces Restructuring Plan and Leadership Changes

December 14, 2020

Assertio Reports Third Quarter 2020 Financial Results

November 5, 2020

Assertio to Release Third Quarter 2020 Financial Results and Host Webcast on November 6, 2020

October 22, 2020

Assertio Reports Second Quarter 2020 Financial Results

August 6, 2020

Assertio to Release Second Quarter 2020 Financial Results and Host Webcast on August 7, 2020

July 19, 2020

Assertio Therapeutics Announces First-Quarter 2020 Results

May 10, 2020

Assertio Therapeutics Announces its Virtual 2020 Annual Meeting on May 19, 2020, and Mailing of its Joint Proxy Statement/Prospectus

April 19, 2020

Assertio Therapeutics Announces Completion and Final Results of the Offer to Purchase All of Its Issued and Outstanding 2.50% Senior Convertible Notes due 2021 and 5.00% Senior Convertible Notes due 2024

April 7, 2020

Assertio Therapeutics Agrees to Merge with Zyla Life Sciences to Create Synergistic Portfolio of Neurology and Non-Opioid Pain Products

March 15, 2020

Assertio Therapeutics Announces Offer to Purchase All of Its Issued and Outstanding 2.50% Senior Convertible Notes Due 2021 and 5.00% Senior Convertible Notes Due 2024

March 10, 2020

Assertio Therapeutics Announces Fourth-Quarter and Full-Year 2019 Financial Results

March 8, 2020

Assertio Therapeutics Announces Repurchase of Approximately $188.0 Million of its Outstanding Convertible Debt

February 18, 2020

Assertio Therapeutics Announces Closing of Sale of NUCYNTA® Franchise to Collegium Pharmaceutical for $375.0 Million

February 12, 2020

Assertio Therapeutics Announces Sale of NUCYNTA® Franchise to Collegium Pharmaceutical for $375.0 Million

February 5, 2020

Assertio Therapeutics Announces Closing of Gralise® Sale to Alvogen and Expects Full-Year 2019 Neurology Franchise Net Sales Above Upper End of Prior Guidance

January 12, 2020

Assertio Therapeutics Announces Sale of Gralise® for Total Transaction Value of $127.5 Million

December 11, 2019

Assertio Therapeutics Announces Third-Quarter 2019 Results

November 5, 2019

Assertio Therapeutics to Report Third-Quarter 2019 Financial Results After the Close of Markets on Wednesday, November 6, 2019

October 22, 2019

Assertio Therapeutics Provides Regulatory Update on Long-Acting Cosyntropin

October 20, 2019

Assertio Therapeutics Announces Appointment of Dr. David Wheadon to its Board of Directors

September 29, 2019

← Newer news releases

Calls

The 5 newest of 20 calls. Every call is listed under its year.

Decks